Friday Satellite Symposium on Molecular Targets in T-Cell Disorders: Progress in Improving Therapeutic Outcomes, preceding the 49th ASH Annual Meeting.


Overview and Purpose

The Molecular Targets in T-Cell Disorders: Progress in Improving Therapeutic Outcomes symposium is intended to update physicians on newer treatment regimens currently undergoing clinical study in T-cell lymphomas. This histology represents approximately 10%-15% of all non-Hodgkin lymphomas, with approximately 5000 new cases diagnosed each year in the United States. T-cell lymphomas comprise a heterogeneous group of malignancies. Patients with T-cell lymphoma have a poorer prognosis compared to those with aggressive B-cell malignancies, and regimens such as CHOP that have been traditionally used to treat T-cell lymphomas have yielded low response rates. The rates of complete remission in response to CHOP therapy in T-cell lymphoma are highly variable, and 5-year survival rates are < 30%, highlighting the need for therapies designed for patients with T-cell lymphoma. New treatment options are being explored in clinical trials, including monoclonal antibodies targeting T-cell surface antigens and small-molecule inhibitors of cell proliferation processes such as histone acetylation/deacetylation and regulation of protein turnover by the proteasome.

Target Audience

This educational program is directed toward medical oncologists, hematologists, and fellows in training involved in the treatment of patients with T-cell lymphomas. Oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of cancer are also invited to attend.

CME Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Learning Objectives

At the conclusion of this symposium, you should be able to:
  • Discuss the classification and molecular pathogenesis of T-cell lymphomas
  • Review the recent advances in the standard of care for peripheral T-cell lymphoma
  • Evaluate the rationale for inhibition of folate biosynthesis in T-cell lymphoma and review current clinical studies of folate inhibitors in T-cell lymphoma
  • Assess the clinical activity of monoclonal antibodies that are currently being investigated in the treatment of T-cell lymphoma
  • Outline clinical studies involving novel small-molecule inhibitors in the treatment of T-cell lymphoma


Acknowledgement

Supported by an educational grant from

Allos Therapeutics Inc.